Leerink Partners Reiterates Outperform Rating on Fulcrum Therapeutics (FULC)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St set for higher open as Anthropic's IPO filing sharpens AI focus
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
| (NASDAQ: FULC) | Delayed: 3.68 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.68 | 52 Week High | $ | |||
| Open | $3.68 | 52 Week Low | $ | |||
| Day High | $3.68 | P/E | N/A | |||
| Day Low | $3.68 | EPS | $ | |||
| Volume | 769 | |||||
